LONDON, 15 August 2024. Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces the shelf-life extension of KLOXXADO (naloxone HCl) nasal spray 8mg from 24 to 36 months. KLOXXADO now features updated packaging with a 36-month dating, starting with the product manufactured in March 2024.
Moreover, KLOXXADO contains twice as much naloxone per spray as Narcan Nasal Spray 4mg in a ready-to-use nasal spray to reverse the effects of opioid overdose, providing an important treatment option in addressing the overdose epidemic.
However, Medical professionals have long recognized naloxone as an important, safe, and effective treatment in the fight against opioid overdose. Organizations, including the CDC and the American Medical Association, have noted that a higher dose of naloxone may be required to revive a patient experiencing poisoning from illicit fentanyl or other opioids due to the increasing prevalence of illicitly manufactured synthetic opioids. As a ready-to-use nasal spray that contains twice as much naloxone per spray than Narcan Nasal Spray 4mg, KLOXXADO provides an important lifesaving treatment option.
Also Read: Otrivin Nasal Mist: Breathe Easy Again
“The shelf-life extension is good news for frontline responders and the thousands of people who carry KLOXXADO and who may need to use it at a moment’s notice to reverse an overdose,” said Dr. Hafrun Fridriksdottir, President, Hikma Generics. “We have a role to play in the fight against illicit fentanyl and as we approach National Overdose Awareness Day on August 31st , it’s gratifying that we are supplying an important medicine that can save lives and help address the deadly overdose epidemic.”
